| Frequency, treatment and outcome of immune-related toxicities in patients with immune-checkpoint inhibitors for advanced melanoma: results from an institutional database analysis F Dimitriou, R Staeger, M Ak, M Maissen, K Kudura, MJ Barysch, ... Cancers 13 (12), 2931, 2021 | 22 | 2021 |
| An optimized tissue dissociation protocol for single-cell RNA sequencing analysis of fresh and cultured human skin biopsies B Burja, D Paul, A Tastanova, SG Edalat, R Gerber, M Houtman, M Elhai, ... Frontiers in Cell and Developmental Biology 10, 872688, 2022 | 17 | 2022 |
| Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study NB Wagner, MM Lenders, K Kühl, L Reinhardt, F André, M Dudda, N Ring, ... Journal for ImmunoTherapy of Cancer 9 (5), 2021 | 15 | 2021 |
| Tebentafusp in patients with metastatic uveal melanoma: a real-life retrospective multicenter study D Tomsitz, T Ruf, M Heppt, R Staeger, E Ramelyte, R Dummer, ... Cancers 15 (13), 3430, 2023 | 4 | 2023 |
| Saliency-enhanced content-based image retrieval for diagnosis support in dermatology consultation: Reader study M Gassner, JB Garcia, S Tanadini-Lang, F Bertoldo, F Fröhlich, ... JMIR dermatology 6 (1), e42129, 2023 | 2 | 2023 |
| 1772P Demonstration of T cell redirection and immune activation in skin rash following tebentafusp treatment R Stäger, S Stanhope, A Greenshields-Watson, L Collins, E Ramelyte, ... Annals of Oncology 32, S1215, 2021 | 2 | 2021 |
| Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma NMR Prieto, P Turko, C Zellweger, TDL Nguyen-Kim, R Staeger, E Bellini, ... Melanoma Research 34 (2), 166-174, 2024 | 1 | 2024 |
| More data are needed to confirm the utility of screening for atypical fibroxanthoma and pleomorphic dermal sarcoma recurrence JP Pham, R Staeger, JW Frew Journal of the American Academy of Dermatology, 2024 | 1 | 2024 |
| Proteomic profiling of advanced melanoma patients to predict therapeutic response to anti-PD-1 therapy N Zila, OM Eichhoff, I Steiner, T Mohr, A Bileck, PF Cheng, A Leitner, ... Clinical Cancer Research 30 (1), 159-175, 2024 | 1 | 2024 |
| Intralesional oncolytic virotherapy with talimogene laherparepvec in patients with cutaneous lymphomas and non-melanoma skin cancers. E Ramelyte, L Pawlik, P Turko, F Sella, NM Roshardt Prieto, R Stäger, ... Journal of Clinical Oncology 41 (16_suppl), 9581-9581, 2023 | 1 | 2023 |
| Recurrent squamous cell carcinoma of the perianal skin: a case report R Staeger, E Ramelyte, R Dummer ESMO open 5 (3), 2020 | 1 | 2020 |
| Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma NM Roshardt Prieto, P Turko, C Zellweger, TDL Nguyen-Kim, R Staeger, ... Melanoma Research 34 (2), 166-174, 2024 | | 2024 |
| Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland R Staeger, JM Martínez-Gómez, P Turko, E Ramelyte, L Kraehenbuehl, ... Cancers 16 (5), 854, 2024 | | 2024 |
| Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy NB Wagner, MM Lenders, K Kühl, L Reinhardt, M Fuchß, N Ring, R Stäger, ... European Journal of Cancer 196, 113425, 2024 | | 2024 |
| Multiomics analysis reveals a Type III driven immune response in immunotherapy-induced toxicity in melanoma and identifies potential new therapeutic targets M Levesque, F Dimitriou, P Cheng, A Saltari, K Schaper-Gerhardt, ... | | 2023 |
| Successful long‐term treatment of pyoderma gangrenosum with secukinumab F Froehlich, M Dreßler, R Staeger, LE French, B Meier‐Schiesser JEADV Clinical Practice 2 (2), 316-319, 2023 | | 2023 |
| 1607 Multiomic analysis of immune-related adverse events (irAEs) in melanoma patients treated with anti-PD1-based immune checkpoint inhibitors (ICIs) F Dimitriou, P Cheng, A Saltari, R Staeger, A Tastanova, M Levesque, ... Journal of Investigative Dermatology 143 (5), S275, 2023 | | 2023 |
| 243P Skin biopsies for pharmacodynamic studies of tebentafusp: A novel bispecific molecule against the melanocytic antigen gp100 R Stäger, A Tastanova, E Ramelyte, MP Levesque, R Dummer, ... Immuno-Oncology and Technology 16, 2022 | | 2022 |
| Robinson MD and Frank-Bertoncelj M (2022) An Optimized Tissue Dissociation Protocol for Single-Cell RNA Sequencing Analysis of Fresh and Cultured Human Skin Biopsies B Burja, D Paul, A Tastanova, SG Edalat, R Gerber, M Houtman, M Elhai, ... Front. Cell Dev. Biol. 10: 872688. doi: 10.3389/fcell, 2022 | | 2022 |
| Demonstration of T cell redirection and immune activation in skin rash following tebentafusp treatment R Staeger, S Stanhope, A Greenshields-Watson, L Collins, E Ramelyte, ... EXPERIMENTAL DERMATOLOGY 31 (2), E52-E52, 2022 | | 2022 |
